Deciphering the Single-cell Transcriptome Network in Keloids with Intra-lesional Injection of Triamcinolone Acetonide Combined with 5-fluorouracil
Overview
Affiliations
Objectives: Keloid is a highly aggressive fibrotic disease resulting from excessive extracellular matrix deposition after dermal injury. Intra-lesional injection of triamcinolone acetonide (TAC) in combination with 5-fluorouracil (5-FU) is a commonly used pharmacological regimen and long-term repeated injections can achieve sustained inhibition of keloid proliferation. However, the molecular mechanisms underlying the inhibitory effect on keloids remain insufficiently investigated.
Methods And Materials: This study performed single-cell RNA sequencing analysis of keloids treated with TAC+5-FU injections, keloids, and skins to explore patterns of gene expression regulation and cellular reprogramming.
Results: The results revealed that TAC+5-FU interrupted the differentiation trajectory of fibroblasts toward pro-fibrotic subtypes and induced keloid atrophy possibly by inhibiting the FGF signaling pathway in intercellular communication. It also stimulated partial fibroblasts to develop the potential for self-replication and multidirectional differentiation, which may be a possible cellular source of keloid recurrence. T cell dynamics demonstrated elevated expression of secretory globulin family members, which may be possible immunotherapeutic targets. Schwann cell populations achieved functional changes by increasing the proportion of apoptotic or senescence-associated cell populations and reducing cell clusters that promote epidermal development and fibroblast proliferation.
Conclusions: Our findings elucidated the molecular and cellular reprogramming of keloids by intra-lesional injection of TAC+5-FU, which will provide new insights to understand the mechanism of action and therapeutic targets.
Leveraging Microneedles for Raised Scar Management.
Jin Z, Kim Y, Lim J Polymers (Basel). 2025; 17(1.
PMID: 39795511 PMC: 11722619. DOI: 10.3390/polym17010108.
Komulainen T, Daymond P, Hietanen K, Kaartinen I, Jarvinen T Front Med (Lausanne). 2024; 11:1293028.
PMID: 38495113 PMC: 10943694. DOI: 10.3389/fmed.2024.1293028.